Records containing: Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2021-08-13Impact of an Artificial Intelligence Platform (DERM) on the Healthcare Resource Utilisation (HRU) Needed to Diagnose Skin Cancer When Used as Part of a United Kingdom-based Teledermatology Service
-
CLINICAL_TRIALS study record update · 2021-08-13Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
-
CLINICAL_TRIALS study record update · 2021-08-11A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
-
CLINICAL_TRIALS study record update · 2021-08-03Camrelizumab Combined With Anlotinib and Nab-paclitaxel in Patients With Untreated Advanced Mucosal Melanoma:a Single-arm, Multicenter, Open-label Study
-
CLINICAL_TRIALS study record update · 2021-08-02Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2021-07-22A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
-
CLINICAL_TRIALS study record update · 2021-07-16Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
-
CLINICAL_TRIALS study record update · 2021-07-12A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
-
CLINICAL_TRIALS study record update · 2021-07-09A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated
-
CLINICAL_TRIALS study record update · 2021-07-07Exploratory Study on Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma
-
CLINICAL_TRIALS study record update · 2021-07-01Risk Information and Skin-cancer Education for Undergraduate Prevention
-
CLINICAL_TRIALS study record update · 2021-07-01A Multicenter, Single Arm, Phase 2 Clinical Study on the Combination of Radiation Therapy and Ipilimumab, for the Treatment of Patients With Melanoma and Brain Metastases
-
CLINICAL_TRIALS study record update · 2021-06-24An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2021-06-21Study to Assess the Safety and Tolerability of ECI-006 mRNA Immunotherapy by Intranodal Administration in Melanoma: (1) Following Surgical Resection, and (2) in Patients With Stable Disease After Standard of Care Immunotherapy Treatment
-
CLINICAL_TRIALS study record update · 2021-06-18(ImmunotheRapy SyMptom CApture) A RANDOMIZED CONTROLLED TRIAL OF SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
-
CLINICAL_TRIALS study record update · 2021-06-16Open Prospective Clinical Trial to Develop the Computer Software (Intelligent Prognostic System) for Predicting the Efficacy of Anti-PD-1 Immunotherapy of Melanoma Patients in Routine Practice
-
CLINICAL_TRIALS study record update · 2021-06-15A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
-
CLINICAL_TRIALS study record update · 2021-06-15Clinical Trial of Nivolumab (BMS-936558) Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma CheckMate 401: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 401
-
CLINICAL_TRIALS study record update · 2021-05-28A Rollover Protocol For Patients Who Received Tremelimumab (CP-675,206 ) In Other Protocols
-
CLINICAL_TRIALS study record update · 2021-05-10BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs (BLOOD Trial)
-
CLINICAL_TRIALS study record update · 2021-05-05Phase 1 Study of Anti-PD-1 Antibody MK-3475 and Peginterferon Alfa-2b for Advanced Melanoma
-
CLINICAL_TRIALS study record update · 2021-04-29A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63)
-
CLINICAL_TRIALS study record update · 2021-04-28A lead-in Phase I Followed by a Phase II Clinical Trial on the Combination of Dabrafenib, Trametinib and the Autophagy Inhibitor Hydroxychloroquine in BRAF/MEK Inhibitor-pretreated Patients With Advanced BRAF V600 Mutant Melanoma
-
CLINICAL_TRIALS study record update · 2021-04-28Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma: A Randomized Patient-focused Trial of Delivering the ASICA Intervention as a Means to Earlier Detection of Recurrent and Second Primary Melanoma
-
CLINICAL_TRIALS study record update · 2021-04-26VECODUE A Phase II Trial of Vemurafenib Plus Cobimetinib in Patients Treated With Prior First-line Systemic Immunotherapy for Inoperable Locally Advanced or Metastatic Melanoma